Our own Colin MacKay, CEO of Symbiosis Pharmaceutical Services, was recently invited to participate in a roundtable discussion assessing the trends driving parenteral manufacturing for an article for Contract Pharma.
The resulting article explores the trends that are fuelling the demand for parenteral manufacturing, the changing structure of the CMO industry and the impact on biotech and small pharma companies needing to outsource their clinical manufacturing requirements.
In the article, Colin explains: “There are a number of factors influencing the growing demand for aseptically-processed parenteral products. The continued growth of the biotech sector and increased funding available are major drivers, while mergers and acquisitions within the contract manufacturing organization (CMO) space are changing the landscape and service options available for drug developers.”
You can read the full discussion here, via Contract Pharma.